… Major questions still need to be answered to optimize COVID-19 treatment for nonhospitalized
patients. What is the benefit of therapies in lower-risk patients, such as those who have …

… of COVID-19 infections, two basic therapeutic strategies are … all non-hospitalized adults with
mild to moderate COVID-19 [… disease, several antiviral therapeutic options are available to …

… In a randomized placebo-controlled Phase 3 study in non-hospitalized adult patients with
COVID-19 at high risk of progressing to severe illness, a single subcutaneous dose of …

… of adult subjects hospitalized with severe COVID-19, high-flow oxygen therapy or non-invasive
mechanical ventilation, and/or with high levels of systemic inflammation indices. …

… Patients Who Are Immunocompromised Initial treatment of COVID-19 for nonhospitalized
patients who are immunocompromised is the same as for other patients: standardduration …

… in the first-in-human study in hospitalized patients for both the 700 and 7000 mg doses
21 . … trial for the evaluation of therapeutics for early COVID-19 in non-hospitalized adults (see …

… non-hospitalized patients with mild to moderate COVID-19 prior to the current Omicron surge
[11]. C+I bind to the spike protein epitope, preventing attachment to the ACE 2 receptor [12]…

… of Health (NIH) COVID-19 Treatment Guidelines after each therapeutic’s section to provide
… in high-risk, nonhospitalized patients with mild or moderate COVID-19. The PINETREE study …

… Currently, in the USA, only bebtelovimab is recommended in non-hospitalized adult patients
with COVID-19 at risk of disease progression when antiviral treatment is unavailable or …

… trials within the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401
platform were performed at US ambulatory sites. Nonhospitalized adults 18 years or …